Blog December 2, 2020
Mobile App Developers May Benefit from FDA's Draft "Wellness" Guidance Proposing Not to Regulate Some Low Risk Medical Devices
- Person title
On January 16, 2015, the FDA released a draft guidance on "General Wellness: Policy for Low Risk Devices" that proposes a novel rationale for not regulating what might otherwise be considered medical devices.
The traditional way of avoiding FDA device regulation is not to make claims that a product is intended for the diagnosis of a disease or condition, nor for the cure, mitigation, treatment, or prevention of disease. The FDA's draft guidance recognizes that products that do not make such claims are likely not devices.
In a new twist, the draft guidance document proposes another category of unregulated "wellness" products that are intended to promote, track, and/or encourage personal choices that may help to (i) reduce the risk of or (ii) help live well with certain chronic diseases or conditions. Such claims may refer to specific diseases or conditions only when it is well understood and generally accepted (e.g. described in peer-reviewed scientific publications) that healthy choices may reduce the risk or impact of a chronic disease or condition. What constitutes a "peer-reviewed scientific publication" or other evidence of being well understood and generally accepted may be a matter of some debate.
This approach is similar to the FDA's regulation of "structure/function" claims for dietary supplements, which must be substantiated with valid scientific evidence. Such claims typically refer to maintaining healthy structure or function of the body or general well-being.
Whether the FDA ultimately adopts this approach for not regulating certain low risk medical devices in a final guidance or rulemaking remains to be seen, but the proposal represents a potentially exciting new development in the regulation (or lack thereof) of medical devices, particularly mobile apps that are designed to provide people with real-time information to make well-informed choices that may affect their health.
The draft guidance is available here. Public comments must be made within 90 days of publication in the Federal Register (by approximately mid-April).
The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.
Blog December 9, 2019
Blog July 26, 2019
Heightened Scrutiny of Specimens of Use at U.S. Trademark Office
Blog July 3, 2019
Legal Alert: New Rule Requires Foreign-Domiciled Trademark Applicants, Registrants, and Parties at TTAB to Be Represented by U.S. Attorney
Blog April 2, 2018
USPTO Pilot Program Regarding Specimen Authenticity
Blog July 5, 2017
U.S. Trademark Office Clarifies Filing Deadlines for Resurrecting Dead Applications and Registrations
Blog June 8, 2017
Even GOOGLE Can Google After All
Blog May 19, 2017
What Does The "In" in "Incontestable" Mean?
Blog February 7, 2017
U.S. Trademark Office Sharpens Machete for Pruning Deadwood
Blog February 3, 2017
FDA Final Guidance on Nonproprietary Names of Biological Products
Article March 8, 2023
Senior Principal Terry Mahn Authors Medical Device + Diagnostic Industry Article "This Company's False Compliance With CISPR 11 Resulted in a $12 Million FCA...
Article February 17, 2023
Principals Patrick Darno and Peter Fasse Author "Patent Strategies for Protecting Bioinformatics Inventions" for IAM
Article February 3, 2023
Fish & Richardson Attorneys Author IAM Article "Neglect Begets Opportunity in Femtech IP"
Blog January 17, 2023
Biosimilars 2022 Year in Review
Article October 20, 2022
Life Sciences Entrepreneur Sourcebook | Intellectual Property: What It Is and Why You Should Care
Blog September 15, 2022
Legal Alert: What to Know About the USPTO's Duty of Candor Guidance Regarding FDA Submissions
Blog January 11, 2022
Biosimilars 2021 Year in Review
Blog December 2, 2020
IP and Cannabis: The Current Landscape
Blog August 8, 2019
5G Developments: From Rollout to Regulation
Article April 20, 2017